ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1965

Artificial Intelligence Assisted Interpretation of Lung Ultrasound Imaging for the Detection of Interstitial Lung Disease
Abstract Number: 2116

Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound
Abstract Number: 1956

Artificial Intelligence Enhanced Analysis of Nailfold Capillaries by Dermatoscopy in Rheumatology Centers
Abstract Number: 1744

Artificial Intelligence: A Novel Tool in the Belt for Improving Rheumatoid Arthritis Outcomes in the National Health Service, United Kingdom
Abstract Number: 2437

Aryl Hydrocarbon Receptor as an Intrinsic Novel Checkpoint That Inhibits TLR7-induced B-cell Activation in SLE
Abstract Number: 0525

Assess the Effect of Increasing the Dose of Folic Acid Supplementation in Patients of Rheumatoid Arthritis with Methotrexate Intolerance – A Randomised Controlled Trial
Abstract Number: 1304

Assessing Knowledge and Aptitude in Antinuclear Antibody Testing Among Internal Medicine Residents
Abstract Number: 1957

Assessing Left Ventricular Hemodynamic Forces in Systemic Sclerosis Patients: Pilot Study
Abstract Number: 1263

Assessing Lupus Low Disease Activity State in the Pediatric Rheumatology Clinic: Baseline Data Collection from a Pediatric Lupus Collaborative
Abstract Number: 1981

Assessing Major Adverse Cardiovascular Events (MACE) Risk in Common Rheumatology Treatments
Abstract Number: 1182

Assessing Male Pelvic Floor Contractions Using a Novel External Pressure Device and Ultrasound
Abstract Number: 1062

Assessing Musculoskeletal Symptom Burden in a Cohort of Patients with Hidradenitis Suppurativa Using the IDEOM MSK-Q
Abstract Number: 1452

Assessing Responsiveness of Outcome Measures for Children with Axial Juvenile Spondyloarthritis (JSpA)
Abstract Number: 1770

Assessing S100A4 and Myofibroblast Phenotypes in the Pathogenesis of Cardiac and Cutaneous Neonatal Lupus
Abstract Number: 1513

Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].